Four-Year Entecavir Treatment in Nucleoside-Naïve HBeAg(+) Patients: Results from Studies ETV-022 and -901
S Han, T Chang, YC Chao, SK Yoon, RG Gish, H Cheinquer, FJ Carrilho, H Zhang, H Brett-Smith, N Spiegelmacher, A Schwendel, T Pichl, I Reeb, R Hindes · Zeitschrift für Gastroenterologie · 2008 · Heft 09
Bibliografische Angaben
Zusammenfassung
Aims: Entecavir (ETV) 0.5mg demonstrated superior virologic suppression compared to lamivudine (LVD) 100mg in study ETV-022. One hundred and eighty-three entecavir-treated patients from ETV-022 enrolled in rollover study ETV-901. We present efficacy and safety results in a cohort of patients from ETV studies -022 and -901 who received a total of 4 years of therapy with ETV. Methods: The nucleoside-naïve HBeAg(+) 4-year cohort consists of ETV patients who completed ETV-022 and enrolled into ETV-901 with a treatment gap ≤35 days. In ETV-901, patients were treated with 1mg of ETV. The proportions of patients with H…
